$110M injection powers up Peninsula vaccine maker — but not for COVID-19

Aiming to beat big-name competition with a super-powered pneumonia vaccine, SutroVax Inc. raised $110 million to push into a clinical trial that could produce data in 2022. That timeline is likely too late for the Foster City-based company to attack one of the signature results of COVID-19 — the disease that since its introduction in December has killed more than 21,000 people worldwide — but it could be a powerful new tool to prevent pneumonia. The Series D round was led by new investors RA…

Click to view original post